Cash and cash equivalents

Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update

Retrieved on: 
Thursday, May 27, 2021
General Health, Professional services, Health, Finance, New York Stock Exchange, Tel Aviv Stock Exchange, Cuban American National Foundation, Cash and cash equivalents, Money, Economy, Service companies

(NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2021.

Key Points: 
  • (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2021.
  • The Company expects to complete enrollment in Q3 2021 and report topline results in Q4 2021.
  • The decrease in financial expense, net was mainly due to finance income recorded from revaluation of our short-term investment.
  • As of March 31, 2021, Can-Fite had cash and cash equivalents and short term deposits of $11.24 million as compared to $8.26 million at December 31, 2020.

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

Retrieved on: 
Monday, May 17, 2021
Asset, Cash, Cash and cash equivalents, Leukemia, Acute myeloid leukemia, Myelodysplastic syndrome

Ms. Pinto was most recently VP of Finance and Operations at Tizona Therapeutics and is a Certified Public Accountant.\nFirst Quarter 2021 Financial Results:\nCash and Cash Equivalents: Cash and cash equivalents as of March 31, 2021 were $429.9 million.

Key Points: 
  • Ms. Pinto was most recently VP of Finance and Operations at Tizona Therapeutics and is a Certified Public Accountant.\nFirst Quarter 2021 Financial Results:\nCash and Cash Equivalents: Cash and cash equivalents as of March 31, 2021 were $429.9 million.
  • These expenses for the three months ended March 31, 2021, were $9.8 million, compared to $3.8 million for the same prior-year period.
  • These expenses for the three months ended March 31, 2021, were $4.4 million, compared to $1.5 million for the same prior-year period.
  • ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as myelodysplastic syndromes (\xe2\x80\x9cMDS\xe2\x80\x9d) and acute myeloid leukemia (\xe2\x80\x9cAML\xe2\x80\x9d).

AgroFresh Solutions Reports Results for First Quarter of 2021

Retrieved on: 
Thursday, May 13, 2021
Money, Earnings before interest, taxes, depreciation and amortization, Fundamental analysis, Private equity, Profit, XC2, Cash and cash equivalents, Economy

I am energized by the team\'s customer focus and believe that we can chart a path toward consistent profitable top-line growth.

Key Points: 
  • I am energized by the team\'s customer focus and believe that we can chart a path toward consistent profitable top-line growth.
  • "\nNet sales for the first quarter of 2021 increased 18.1%, to $39.0 million, compared to $33.0 million in the first quarter of 2020.
  • Adjusted EBITDA margin increased 240 basis points to 36.3% in the first quarter of 2021, as compared to 33.9% in the prior year period.\nAs of March\xc2\xa031, 2021, cash and cash equivalents were $52.9 million.
  • AgroFresh supports growers, packers and retailers with solutions across the food supply chain to enhance the quality and extend the shelf life of fresh produce.

Prometheus Biosciences Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, May 13, 2021
Medical specialties, Immunology, Clinical medicine, Monoclonal antibodies, XC2, Tumor necrosis factor, Cash and cash equivalents, Prometheus, TNF inhibitor

In IBD specifically, this cytokine has been implicated to contribute to non-response to anti-TNF therapies\nStrengthened leadership and Board of Directors.

Key Points: 
  • In IBD specifically, this cytokine has been implicated to contribute to non-response to anti-TNF therapies\nStrengthened leadership and Board of Directors.
  • As of March 31, 2021, Prometheus Biosciences had cash and cash equivalents of $311.2 million, compared to $54.2 million at the end of 2020.
  • Research and development expenses were $7.8\xc2\xa0million for the three months ended March 31, 2021 compared to $4.3\xc2\xa0million for the three months ended March 31, 2020.
  • The inclusion of forward-looking statements should not be regarded as a representation by Prometheus that any of our plans will be achieved.

Humanigen Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021
Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Asset, Cash, Cash and cash equivalents

As is typical with COVID-19 study results, a pre-print of the LIVE-AIR study was published on-line.

Key Points: 
  • As is typical with COVID-19 study results, a pre-print of the LIVE-AIR study was published on-line.
  • The company also completed a public offering in the second quarter of 2021 with net proceeds of $94.1 million.
  • The proforma balance of cash and cash equivalents at March 31, 2021 with the proceeds from the public offering is $187.0 million.
  • In the second quarter of 2021 the company anticipates the amount of spending on lenzilumab production will be at least the same level as the first quarter of 2021.

89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 12, 2021
XC2, Cash and cash equivalents

As of March 31, 2021, 89bio had cash, cash equivalents, and short-term investments of\xc2\xa0$189.6 million.\nResearch and Development (R&D) Expenses.

Key Points: 
  • As of March 31, 2021, 89bio had cash, cash equivalents, and short-term investments of\xc2\xa0$189.6 million.\nResearch and Development (R&D) Expenses.
  • R&D expenses were\xc2\xa0$10.1 million for the three months ended March 31, 2021, compared to\xc2\xa0$7.8 million for the three months ended March 31, 2020.
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
  • 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.\n'

Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, May 11, 2021
Asset, Cash, Cash and cash equivalents

b'-$133 million in cash, cash equivalents and marketable securities as of March 31, 2021 provides runway into second half of 2023-\nSOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc .

Key Points: 
  • b'-$133 million in cash, cash equivalents and marketable securities as of March 31, 2021 provides runway into second half of 2023-\nSOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc .
  • "\nIn March 2021, Satsuma closed an $80 million private placement of common stock.
  • As of March 31, 2021, the Company had $133.1 million of cash, cash equivalents and marketable securities.
  • For further information, please visit www.satsumarx.com .\nThis press release contains forward-looking statements concerning the business, operations and financial performance and condition of Satsuma Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d), as well as the Company\xe2\x80\x99s plans, objectives and expectations for its business operations and financial performance and condition.

AIkido Pharma Inc. Announces First Quarter 2021 Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 11, 2021
Asset, Cash, Cash and cash equivalents, Severe acute respiratory syndrome, Infectious diseases, Medical specialties, Animal diseases

We continue to make progress with our anti-viral platform with new compounds being tested against influenza virus and testing on SARS-CoV-2.

Key Points: 
  • We continue to make progress with our anti-viral platform with new compounds being tested against influenza virus and testing on SARS-CoV-2.
  • Furthermore, our partnerships with leading academia continues to allow us to pursue pipeline expansion opportunities in emerging and high growth technologies.
  • With approximately$102 millionin cash and cash equivalents on March 31, 2021, and approximately 89.5 million shares outstanding, the Company\'s cash per share equates to approximately $1.15 per share.
  • The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.\n'

Ultimovacs ASA: First Quarter 2021 Result Presentation

Retrieved on: 
Tuesday, May 11, 2021
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Asset, Cash, Cash and cash equivalents, Ulti, T, Games, Publications, Mass media

b'Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 results today.

Key Points: 
  • b'Ultimovacs ASA ("Ultimovacs", ticker ULTI), a pharmaceutical company developing novel immunotherapies against cancer, announces its first quarter 2021 results today.
  • A presentation by the Company\'s management team will take place today on a webcast at 09:00 CEST.
  • (post period event).\nTotal operating expenses amounted to MNOK 31.2 in Q1-21.\nCash flow from operations was MNOK -29.5 in Q1-21.
  • Total cash and cash equivalents amounted to MNOK 409.3 as per 31 March 2021.\nFor further information, please visit www.ultimovacs.com or contact:\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210510005617/en/\n'

Gatos Silver Reports First Quarter 2021 Results

Retrieved on: 
Friday, May 7, 2021
Mining, Minerals, Natural Resources, Branches of biology, Natural sciences, Biology, Asset, Cash, Cash and cash equivalents, Biomineralization, Los Gatos, California

At March 31, 2021, cash and cash equivalents were $31 million.

Key Points: 
  • At March 31, 2021, cash and cash equivalents were $31 million.
  • Esther mineralization is similar to CLG and the Company expects to meaningfully increase the tonnage and metal grades within this zone.
  • Esther is targeted to be the next zone for mine development within the Los Gatos District.
  • No assurance can be given that such future results will be achieved.